Solid Biosciences Statistics
Share Statistics
Solid Biosciences has 39.95M shares outstanding. The number of shares has increased by 5.82% in one year.
| Shares Outstanding | 39.95M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 3.52% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 32.76M |
| Failed to Deliver (FTD) Shares | 222 |
| FTD / Avg. Volume | 0.06% |
Short Selling Information
The latest short interest is 1.76M, so 4.4% of the outstanding shares have been sold short.
| Short Interest | 1.76M |
| Short % of Shares Out | 4.4% |
| Short % of Float | 5.36% |
| Short Ratio (days to cover) | 5.54 |
Valuation Ratios
The PE ratio is -1.27 and the forward PE ratio is -1.97.
| PE Ratio | -1.27 |
| Forward PE | -1.97 |
| PS Ratio | 0 |
| Forward PS | 53 |
| PB Ratio | 0.97 |
| P/FCF Ratio | -1.28 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Solid Biosciences Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.94, with a Debt / Equity ratio of 0.
| Current Ratio | 8.94 |
| Quick Ratio | 8.94 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.76% and return on capital (ROIC) is -68.29%.
| Return on Equity (ROE) | -0.76% |
| Return on Assets (ROA) | -0.58% |
| Return on Capital (ROIC) | -68.29% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.09M |
| Employee Count | 88 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -61.13% in the last 52 weeks. The beta is 1.93, so Solid Biosciences 's price volatility has been higher than the market average.
| Beta | 1.93 |
| 52-Week Price Change | -61.13% |
| 50-Day Moving Average | 4.88 |
| 200-Day Moving Average | 7.39 |
| Relative Strength Index (RSI) | 25.72 |
| Average Volume (20 Days) | 383.12K |
Income Statement
| Revenue | n/a |
| Gross Profit | -76.56M |
| Operating Income | -104.31M |
| Net Income | -96.02M |
| EBITDA | -93.43M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -4.83 |
Balance Sheet
The company has 74.02M in cash and 26.27M in debt, giving a net cash position of 47.75M.
| Cash & Cash Equivalents | 74.02M |
| Total Debt | 26.27M |
| Net Cash | 47.75M |
| Retained Earnings | -658.75M |
| Total Assets | 211.83M |
| Working Capital | 156.64M |
Cash Flow
In the last 12 months, operating cash flow was -94.18M and capital expenditures -1.51M, giving a free cash flow of -95.69M.
| Operating Cash Flow | -94.18M |
| Capital Expenditures | -1.51M |
| Free Cash Flow | -95.69M |
| FCF Per Share | -4.81 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SLDB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -155.31% |
| FCF Yield | -77.01% |
Analyst Forecast
The average price target for SLDB is $16, which is 414.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $16 |
| Price Target Difference | 414.5% |
| Analyst Consensus | Buy |
| Analyst Count | 11 |
Stock Splits
The last stock split was on Oct 28, 2022. It was a backward split with a ratio of 1:15.
| Last Split Date | Oct 28, 2022 |
| Split Type | backward |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | -3.4 |
| Piotroski F-Score | 2 |